Recent Dealmaking (05/2003)
Executive Summary
Summarizing the month in European dealmaking.You may also be interested in...
Kissei Discussing Rovatirelin Path After Mixed Phase III Results
Japanese firm in discussions with regulator as high-need novel therapy for spinocerebellar degeneration misses endpoint but shows promise in pooled analysis.
QUOTED. 24 January 2020. Megan McSeveney.
The FDA has readied plans for hastened emergency-use approvals of coronavirus test kits after an infected US citizen returned to Washington State from Wuhan province in China. See what the FDA’s Megan McSeveney said about it here.
A Tale Of Two DMD Drugs: Theme And Variation In Controversial US FDA Reviews
Despite obvious similarities in the contentious reviews of Sarepta’s Vyondys 53 and its predecessor Exondys 51, drug developers should focus on the differences between the two reviews.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports